Neurophyxia was founded in 2008 and is headquartered in ’s-Hertogenbosch, the Netherlands. The company has developed a novel neuroprotectant from early preclinical phase upto current Phase II Clinical Trials, thanks to its dedicated academic team, backed-up by strong business and investment partners.
Neurophyxia is developing 2-iminobiotin (2-IB) for the treatment of cerebral reperfusion injury following stroke, cardiac arrest and birth asphyxia. See for more information neuroprotection.
Co-founder and Chief Scientific Officer
Cacha Peeters- Scholte, MD, PhD
Cacha is working as a pediatric neurologist at Leiden University Medical Center. Her special interest is fetal and neonatal neurology and she has been the driving force behind Neurophyxia since the inception of the project, which started during her PhD. She investigated potential neuroprotective strategies following neonatal hypoxia-ischemia, and identified 2-iminobiotin as a potential neuroprotective drug. From the founding of Neurophyxia she was Chief Scientific Officer. From November 2017 untill May 2018, she was the CEO of Neurophyxia.
Chief Pharmaceutical Development Officer
Leo G. J. de Leede, PharmD, RPh, PhD
Leo is Managing Director of Exelion Bio-Pharmaceutical Consultancy B.V., a company active in pharmaceutical product development. For Neurophyxia he is involved in biopharmaceutics, production, quality control and (early) clinical development. Furthermore he has a broad experience in projects and assignments dealing with pharmaceutical development of dosage forms (conventional and advanced) with both small molecules and biologicals for many other (small) biotech companies. Before that time he has held various managerial positions for pharmaceutical companies like Yamanouchi Europe (currently Astellas Pharma), Gist-brocades, Brocades Pharma, OctoPlus and Organon.
Chief Operation Officer
Drs. Elize van der Hoeven, PharmD
Elize graduated cum laude in Pharmacy at Utrecht University and is a certified specialist (Postgraduate Community Pharmacist Specialist). She has held several positions as pharmacist and consultant within the area of pharmaceutical R&D, quality assurance and strategic advice.
Elize is responsible for the daily operation of Neurophyxia and coordinates the team of specialist consultants.
drs. Elize van der Hoeven, PharmD
Co-founder and safety officer
Huibert has a medical background and has extensive experience in medical innovation management. He has co-founded four companies that develop and bring to the market medical innovations. He has written protocols for, organized and served as medical officer in several international clinical studies. He has also been involved in regulatory affairs, including orphan drug designations.
Suzanne Vink- Hermeling
From 2014 onward Suzanne is the owner of Svinx Consultancy and fullfils the position as pharmaceutical consultant for various biotech companies. Other activities might involve: QA manager/QP for several companies, Performing audits, Performing GMP trainings. In earlier years she has worked at different pharmaceutical (related) companies like Octoplus, Hal Allergy, Halix and Prosensa.
Chief Executive Officer
Ir. Jan van der Hoeven
Jan is an investor in the field of Life Sciences. He has more than 35 years of operating, scientific and financial experience in private equity backed life sciences companies. He has been involved in a number of successful international merger & acquisition deals. He is active in a number of funds to stimulate Life Sciences Companies.
Head of general affairs and finance
Miranda Janssen, MBA
Miranda has a broad experience in administrative activities related to life sciences companies. She has played an important role in the preparation of a variety of business plans for life sciences companies, and has gained significant experience in international merger & acquisition deals. Currently, she is managing director of a private life sciences incubator called WesterToren Innovation Centre and is also involved as a fund manager in Brabant Life Sciences Seed Fund that stimulates Life Sciences Companies.